title: Factor V Leiden (Arg506Gln), a confounding genetic risk factor but not mandatory for the occurrence of venous thromboembolism in homozygotes and obligate heterozygotes for cystathionine beta-synthase deficiency.
abstract: Thrombosis is the major cause of morbidity and mortality in individuals with untreated classical homocystinuria (HCU) due to cystathionine beta-synthase deficiency and characterised by severe hyperhomocysteinaemia. In addition, mild and moderate hyperhomocysteinaemia and Factor V Leiden (FVL; Arg506Gln) have recently been identified as thrombotic risk factors. FVL. which renders resistance to activated Protein C, is the most common inherited genetic risk factor for thrombosis with a high allelic frequency amongst Caucasians. As thrombophilia is a multigenic disorder, 26 individuals with HCU (median age 17.6 years, range 3.5-32.8 years) and 36 obligate heterozygotes (median age 51.5 years, range 34-74 years) were screened for FVL. All the HCU individuals received treatment, except one, within 6 weeks of birth for those who were diagnosed at birth through the national newborn screening programme (n = 20) and at the time of diagnosis for those late detected (n = 5, mean age of starting treatment 4.9 years, range 1.4-11 years). All had been free from venous thrombosis, except one HCU individual and one HCU obligate heterozygote. Neither of the two individuals with venous thrombosis carried FVL. Two independent individuals with HCU (male 14.8 years; female 18.2 years) were heterozygous for FVL (allelic frequency 3.8%) and three independent HCU obligate heterozygotes (males 40 and 45.8 years; female 45.6 years) were also heterozygous for FVL (allelic frequency 4.16%). The findings in this small group suggest that FVL is not a mandatory but a significant confounding risk factor for the occurrence of thrombosis in HCU individuals and additional contributing factors may be required for thrombosis to occur in HCU obligate heterozygotes with FVL heterozygosity. Our data also suggest that treatment of HCU not only reduces the thrombotic risk in patients with isolated HCU but also in those with the additional FVL heterozygosity.
authors.affiliation: National Centre for Inherited Metabolic Disorders, the Children's Hospital, Dublin, Ireland.
authors.forename: S
authors.initials: S
authors.lastname: Yap
authors.forename: K A
authors.initials: KA
authors.lastname: O'Donnell
authors.forename: C
authors.initials: C
authors.lastname: O'Neill
authors.forename: P D
authors.initials: PD
authors.lastname: Mayne
authors.forename: P
authors.initials: P
authors.lastname: Thornton
authors.forename: E
authors.initials: E
authors.lastname: Naughten
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000483:Alleles; D003541:Cystathionine beta-Synthase / Q000172:deficiency*; D005165:Factor V / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D006579:Heterozygote; D006712:Homocystinuria / Q000209:etiology / Q000235:genetics; D006720:Homozygote; D006801:Humans; D020138:Hyperhomocysteinemia / Q000209:etiology / Q000235:genetics; D008297:Male; D008875:Middle Aged; D017354:Point Mutation; D012307:Risk Factors; D020246:Venous Thrombosis / Q000209:etiology* / Q000235:genetics
chemical_list: C095381:factor V Leiden; D005165:Factor V; D003541:Cystathionine beta-Synthase